BR112013025633A2 - nanopartículas à base de lipídios - Google Patents

nanopartículas à base de lipídios

Info

Publication number
BR112013025633A2
BR112013025633A2 BR112013025633A BR112013025633A BR112013025633A2 BR 112013025633 A2 BR112013025633 A2 BR 112013025633A2 BR 112013025633 A BR112013025633 A BR 112013025633A BR 112013025633 A BR112013025633 A BR 112013025633A BR 112013025633 A2 BR112013025633 A2 BR 112013025633A2
Authority
BR
Brazil
Prior art keywords
lipid
compositions
based nanoparticles
amyloid
liposomal
Prior art date
Application number
BR112013025633A
Other languages
English (en)
Portuguese (pt)
Inventor
Annapragada Ananth
A Tanifum Eric
Dasgupta Indrani
L Eriksen Jason
c cook Stephen
Original Assignee
Alzeca Biosciences Llc
Board Of Regents Of The Univ Of Houston System
Univ Texas
Texas Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013025633(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzeca Biosciences Llc, Board Of Regents Of The Univ Of Houston System, Univ Texas, Texas Childrens Hospital filed Critical Alzeca Biosciences Llc
Publication of BR112013025633A2 publication Critical patent/BR112013025633A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
BR112013025633A 2011-04-06 2012-04-06 nanopartículas à base de lipídios BR112013025633A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (1)

Publication Number Publication Date
BR112013025633A2 true BR112013025633A2 (pt) 2017-08-08

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025633A BR112013025633A2 (pt) 2011-04-06 2012-04-06 nanopartículas à base de lipídios

Country Status (14)

Country Link
US (1) US9801957B2 (enExample)
EP (2) EP3366313A1 (enExample)
JP (3) JP6212032B2 (enExample)
KR (2) KR101973063B1 (enExample)
CN (1) CN104144708B (enExample)
AU (3) AU2012239888B9 (enExample)
BR (1) BR112013025633A2 (enExample)
CA (1) CA2831480C (enExample)
DK (1) DK2694116T3 (enExample)
ES (1) ES2685824T3 (enExample)
MX (1) MX357227B (enExample)
PL (1) PL2694116T3 (enExample)
PT (1) PT2694116T (enExample)
WO (1) WO2012139080A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2694116T3 (pl) * 2011-04-06 2018-12-31 Board Of Regents Of The University Of Texas System Nanocząstki na bazie lipidów
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
US9512092B2 (en) 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
US9744251B2 (en) * 2014-10-08 2017-08-29 Texas Children's Hospital MRI imaging of amyloid plaque using liposomes
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
WO2017201091A1 (en) * 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
CN110022859B (zh) 2016-11-30 2022-10-28 德克萨斯州儿童医院 具有独特的mr特征用于脂质体19f mri探针的亲水性氟化分子
WO2020154623A1 (en) * 2019-01-24 2020-07-30 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
JP7395759B2 (ja) * 2020-01-29 2023-12-11 テキサス チルドレンズ ホスピタル アミロイド沈着のｍｒｉのための標的造影剤
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
EP4103239A4 (en) * 2020-02-12 2024-03-20 Texas Children's Hospital TARGETED CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING OF ALPHA-SYNUCLEIN DEPOSITS

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JP4829454B2 (ja) * 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
US7029655B2 (en) * 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
AU2002314794A1 (en) * 2001-05-23 2002-12-03 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
JP2005519129A (ja) 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7803351B2 (en) * 2004-08-20 2010-09-28 Washington University Blood brain barrier permeation peptides
DE602005025659D1 (enExample) * 2004-09-23 2011-02-10 Guerbet Sa
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20100062969A1 (en) 2006-04-07 2010-03-11 Hayat Onyuksel Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US20110311457A1 (en) 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
AU2008331764A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
WO2009089396A2 (en) 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010107990A1 (en) 2009-03-19 2010-09-23 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US9334304B2 (en) * 2009-04-02 2016-05-10 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
EP2582674B1 (en) 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Gpr120 receptor agonists and uses thereof
CA2822021C (en) 2011-03-02 2018-01-02 Sensulin, Llc Vesicle compositions
PL2694116T3 (pl) 2011-04-06 2018-12-31 Board Of Regents Of The University Of Texas System Nanocząstki na bazie lipidów
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP6130401B2 (ja) 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
US9377472B2 (en) 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
US9744251B2 (en) 2014-10-08 2017-08-29 Texas Children's Hospital MRI imaging of amyloid plaque using liposomes

Also Published As

Publication number Publication date
DK2694116T3 (en) 2018-09-03
KR20140074868A (ko) 2014-06-18
EP2694116A4 (en) 2015-06-03
PL2694116T3 (pl) 2018-12-31
US9801957B2 (en) 2017-10-31
AU2012239888B9 (en) 2017-10-12
CN104144708A (zh) 2014-11-12
KR20190031334A (ko) 2019-03-25
MX2013011231A (es) 2015-03-05
ES2685824T3 (es) 2018-10-11
CA2831480C (en) 2020-09-29
EP2694116B1 (en) 2018-06-13
AU2012239888A2 (en) 2014-05-08
EP3366313A1 (en) 2018-08-29
AU2012239888B2 (en) 2017-06-22
CN104144708B (zh) 2017-07-28
US20120258044A1 (en) 2012-10-11
JP2018035167A (ja) 2018-03-08
PT2694116T (pt) 2018-10-12
AU2017232156B2 (en) 2019-07-11
KR102035187B1 (ko) 2019-11-08
WO2012139080A3 (en) 2014-05-01
EP2694116A2 (en) 2014-02-12
JP6212032B2 (ja) 2017-10-18
AU2019246775A1 (en) 2019-10-31
CA2831480A1 (en) 2012-10-11
HK1203827A1 (en) 2015-11-06
KR101973063B1 (ko) 2019-04-30
JP2019151664A (ja) 2019-09-12
JP2014523854A (ja) 2014-09-18
AU2012239888A1 (en) 2013-11-07
WO2012139080A2 (en) 2012-10-11
MX357227B (es) 2018-07-02
JP6533813B2 (ja) 2019-06-19
AU2017232156A1 (en) 2017-10-12
AU2017232156C1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
BR112013025633A2 (pt) nanopartículas à base de lipídios
BR112014009866A2 (pt) formulações de anticorpos e métodos
BR112014004544A2 (pt) modificação com peg de nanopartículas com h-fosfonatos
BR112014013526A8 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
BR112015014555A2 (pt) composições pesticidas e processos relacionados a isso
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
BR112014011594A2 (pt) anticorpos anti-il-36r
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
BR112015029090A2 (pt) compostos de 3,4-di-hidroisoquinolin-2(1h)-ila
EA201270480A1 (ru) Новые соединения
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015000329A2 (pt) formulações de diclofenac
BR112014002758A2 (pt) composições para cuidados pessoais contendo zinco piritiona submetido à secagem
GB201105137D0 (en) Therapeutic molecules for use in the suppression of Parkinson's disease
BR112013022052A2 (pt) ligantes antagonísticos de dr3
PH12018502580A1 (en) Formulations for paddy rice fields
BR112015006705A2 (pt) antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático
BR112014000637A2 (pt) diagnóstico do mal de alzheimer
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
EP2709531A4 (en) NONINVASIVE LIVESTOCK DETERMINATION BY CREEPER DISPERSION
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements